Patients with immunosuppressive conditions, particularly those being treated with tumor necrosis factor inhibitors, are vulnerable to infections, but rheumatologists have mostly been hesitant to use any live virus vaccines in these patients, said Jeffrey R. Curtis, MD, MS, MPH, professor of medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham.
Patients with immunosuppressive conditions, particularly those being treated with tumor necrosis factor (TNF) inhibitors, are vulnerable to infections, but rheumatologists have mostly been hesitant to use any live virus vaccines in these patients, said Jeffrey R. Curtis, MD, MS, MPH, professor of medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham.
Transcript
One of the big issues for patients with rheumatic diseases is that they can be immunocompromised because of the TNF inhibitors. What was the VERVE trial studying and what are the clinical implications of the findings?
So, as you’ve alluded to, patients with immunosuppressive conditions—rheumatoid arthritis, inflammatory bowel disease, psoriatic arthritis—are on a variety of immunomodulatory or immunosuppressive medications. Whether it’s those diseases, or those treatments that put people at higher risk of infection is a little bit unclear, but at the end of the day, they’re at higher risk of infection. And that’s been long recognized.
It is unfortunate if one has a vaccine to prevent those infections to not be able to use it. And yet, for well over a decade we have had a live virus vaccine, Zostavax, that is a weakened or attenuated virus that could prevent infection, but we’ve been mostly too afraid to use it in people who have immunocompromised or immune conditions or are on immunosuppressive medications.
So, the background for the VERVE trial is to test the hypothesis: Is it safe and is it effective to give a live virus vaccine to an immunocompromised patient population, which, in this case, was people using anti-TNF therapies.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Rare Autoimmune Disorder Linked With Increased Risk of Certain Skin Cancers
April 21st 2025The risk of some skin cancers, including squamous cell carcinoma, basal cell carcinoma, and non-melanoma skin cancer, was particularly heightened among patients with severe mucous membrane pemphigoid.
Read More
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More